Acarix AB

7AC

Company Profile

  • Business description

    Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.

  • Contact

    Hyllie Boulevard 34
    Regus Malmo
    Malmo215 32
    SWE

    https://www.acarix.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2026

    Employees

    8

Stocks News & Analysis

stocks

Chart of the Week: BHP’s valuation hits historic levels

BHP and peers are trading as if the copper boom is here to stay.
stocks

3 cheap wide moat growth stocks

4 and 5 star companies that can protect and grow their earnings.
stocks

ASX biotech expands diagnostics portfolio after FDA approval

FDA nod adds another growth driver for ASX share.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,905.0030.500.34%
CAC 408,140.5950.310.62%
DAX 4025,537.75135.470.53%
Dow JONES (US)51,461.90631.21-1.21%
FTSE 10010,688.4730.340.28%
HKSE24,535.56178.22-0.72%
NASDAQ25,978.433.14-0.01%
Nikkei 22564,117.83194.830.30%
NZX 50 Index13,736.11113.390.83%
S&P 5007,551.8133.92-0.45%
S&P/ASX 2008,724.5028.000.32%
SSE Composite Index3,877.8113.79-0.35%

Market Movers